Overview

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Status:
Not yet recruiting

Trial end date:
2022-05-31

Target enrollment:

Participant gender:

Summary

The study is being conducted to evaluate the efficacy and safety of Camrelizumab (200mg,q2w) combined with Apatinib(250mg qd) in subjects with PD-L1 positive relapsed or advanced non-small cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Apatinib
Carboplatin
Paclitaxel
Pemetrexed